Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Current Assets (2020 - 2025)

Rani Therapeutics Holdings has reported Current Assets over the past 6 years, most recently at $53.3 million for Q4 2025.

  • Quarterly results put Current Assets at $53.3 million for Q4 2025, up 79.27% from a year ago — trailing twelve months through Dec 2025 was $53.3 million (up 79.27% YoY), and the annual figure for FY2025 was $53.3 million, up 79.27%.
  • Current Assets for Q4 2025 was $53.3 million at Rani Therapeutics Holdings, up from $5.0 million in the prior quarter.
  • Over the last five years, Current Assets for RANI hit a ceiling of $132.4 million in Q3 2021 and a floor of $5.0 million in Q3 2025.
  • Median Current Assets over the past 5 years was $63.2 million (2023), compared with a mean of $64.9 million.
  • Peak annual rise in Current Assets hit 79.27% in 2025, while the deepest fall reached 84.69% in 2025.
  • Rani Therapeutics Holdings' Current Assets stood at $119.6 million in 2021, then decreased by 15.61% to $100.9 million in 2022, then tumbled by 49.62% to $50.8 million in 2023, then tumbled by 41.5% to $29.7 million in 2024, then soared by 79.27% to $53.3 million in 2025.
  • The last three reported values for Current Assets were $53.3 million (Q4 2025), $5.0 million (Q3 2025), and $11.1 million (Q2 2025) per Business Quant data.